• Je něco špatně v tomto záznamu ?

Transplant drugs affect the expression of phase II and antioxidant enzymes in human carcinoma cells HepG2 but not in primary cultures of human hepatocytes: In vitro comparative study

R. Vrzal, P. Illes, Z. Dvorak,

. 2016 ; 68 (5) : 1008-14. [pub] 20160717

Jazyk angličtina Země Polsko

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013659

BACKGROUND: We carried out a test whether or not transplant drugs such as cyclosporine A, Rapamycin (Sirolimus), Tacrolimus, Everolimus and Mycophenolate mofetil affects the expression of phase II enzymes comprising of UDP-glucuronosyltransferases (UGTs) and glutathione-S-transferases (GSTs), and antioxidant enzymes that consist of glutathione reductase (GSR), glutathione peroxidase 1 (GPX1) and heme-oxygenase 1 (HMOX1). METHODS: Experiments were performed in primary cultures of human hepatocytes and in human hepatocarcinoma HepG2 cells, the models of metabolically competent and incompetent cells, respectively. We used quantitative real-time PCR. RESULTS: We found that none of the tested compounds affected the expression of investigated genes in human hepatocytes. On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells. CONCLUSION: We showed that the tested transplant drugs have no effect on the expression of selected phase II and antioxidant enzymes in human hepatocytes. Nevertheless, the experiments carried out in two common and frequently used in vitro cellular models, we emphasize that finding based solely on carcinoma cells must be taken with caution when transposing to in vivo situations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013659
003      
CZ-PrNML
005      
20170426094531.0
007      
ta
008      
170413s2016 pl f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pharep.2016.06.001 $2 doi
035    __
$a (PubMed)27428762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Vrzal, Radim $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic. Electronic address: radim.vrzal@email.cz.
245    10
$a Transplant drugs affect the expression of phase II and antioxidant enzymes in human carcinoma cells HepG2 but not in primary cultures of human hepatocytes: In vitro comparative study / $c R. Vrzal, P. Illes, Z. Dvorak,
520    9_
$a BACKGROUND: We carried out a test whether or not transplant drugs such as cyclosporine A, Rapamycin (Sirolimus), Tacrolimus, Everolimus and Mycophenolate mofetil affects the expression of phase II enzymes comprising of UDP-glucuronosyltransferases (UGTs) and glutathione-S-transferases (GSTs), and antioxidant enzymes that consist of glutathione reductase (GSR), glutathione peroxidase 1 (GPX1) and heme-oxygenase 1 (HMOX1). METHODS: Experiments were performed in primary cultures of human hepatocytes and in human hepatocarcinoma HepG2 cells, the models of metabolically competent and incompetent cells, respectively. We used quantitative real-time PCR. RESULTS: We found that none of the tested compounds affected the expression of investigated genes in human hepatocytes. On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells. CONCLUSION: We showed that the tested transplant drugs have no effect on the expression of selected phase II and antioxidant enzymes in human hepatocytes. Nevertheless, the experiments carried out in two common and frequently used in vitro cellular models, we emphasize that finding based solely on carcinoma cells must be taken with caution when transposing to in vivo situations.
650    _2
$a antioxidancia $x metabolismus $7 D000975
650    _2
$a hepatocelulární karcinom $x metabolismus $7 D006528
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a glukuronosyltransferasa $x metabolismus $7 D014453
650    _2
$a glutathionperoxidasa $x metabolismus $7 D005979
650    _2
$a glutathionreduktasa $x metabolismus $7 D005980
650    _2
$a glutathiontransferasa $x metabolismus $7 D005982
650    _2
$a hemoxygenasa-1 $x metabolismus $7 D051547
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a hepatocyty $x účinky léků $x metabolismus $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x farmakologie $7 D007166
650    _2
$a nádory jater $x metabolismus $7 D008113
650    _2
$a messenger RNA $x metabolismus $7 D012333
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Illes, Peter $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
700    1_
$a Dvorak, Zdenek $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
773    0_
$w MED00165879 $t Pharmacological reports PR $x 1734-1140 $g Roč. 68, č. 5 (2016), s. 1008-14
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27428762 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170426094846 $b ABA008
999    __
$a ok $b bmc $g 1200124 $s 974437
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 68 $c 5 $d 1008-14 $e 20160717 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace